1. Home
  2. EVAX vs BCTX Comparison

EVAX vs BCTX Comparison

Compare EVAX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EVAX

Evaxion Biotech

N/A

Current Price

$3.82

Market Cap

27.4M

Sector

Health Care

ML Signal

N/A

Logo BriaCell Therapeutics Corp.

BCTX

BriaCell Therapeutics Corp.

HOLD

Current Price

$4.32

Market Cap

28.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVAX
BCTX
Founded
2008
2014
Country
Denmark
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
28.8M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
EVAX
BCTX
Price
$3.82
$4.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$11.67
$40.00
AVG Volume (30 Days)
29.9K
212.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$380.95
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$0.61
52 Week High
$12.15
$14.68

Technical Indicators

Market Signals
Indicator
EVAX
BCTX
Relative Strength Index (RSI) 50.85 51.97
Support Level $2.45 $4.10
Resistance Level $5.48 $4.42
Average True Range (ATR) 0.35 0.31
MACD 0.09 0.14
Stochastic Oscillator 41.46 80.30

Price Performance

Historical Comparison
EVAX
BCTX

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: